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Available online 26 April 2014Abstract Two distinct types of embryonic pluripotent stem cells can be established from either the inner cell mass (ICM) of
preimplantation blastocyst (leukemia inhibitory factor (LIF)-dependent embryonic stem cell, ESC, called naive state) or the
epiblast of postimplantation fetuses (fibroblast growth factor 2 (FGF2)-dependent epiblast stem cells, EpiSC, called primed
state). Here, we report that naive pluripotent stem cell was established from the ICM, but maintained its self-renewal by
treatment with FGF2 and mouse embryonic fibroblasts (MEFs) when they were exposed FGF2 during establishment. This
cell line is competent to contribute to chimeric animals, including germ cells, at high efficiency. The ERK1/2, SMAD2/3, and
JAK/STAT3 pathways are essential to maintain self-renewal. Inhibition of ERK1/2 or SMAD2/3 initiates transition to a naive
state ESC-like state, whereas inhibition of JAK/STAT3 promotes a primed EpiSC-like character. Our present results could
provide novel insights into understanding the growth factor environment and ICM plasticity, and mechanisms which orchestrate
the pluripotency of embryonic stem cells and the capacity for chimeric contributions.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction capacity to differentiate into all three germ layer lineages, asSelf-renewing murine embryonic stem cells (mESCs) can be
generated from the inner cell mass (ICM) of preimplantation
blastocysts (Evans and Kaufman, 1981). ESCs can be main-
tained in a stable pluripotent state in vitro and have the⁎ Corresponding author.
E-mail address: semil@ims.u-tokyo.ac.jp (M. Ozawa).
http://dx.doi.org/10.1016/j.scr.2014.04.012
1873-5061/© 2014 The Authors. Published by Elsevier B.V. This is an open a
(http://creativecommons.org/licenses/by-nc-sa/3.0/).well as germ line cells (Bradley et al., 1984). Because of their
unique characteristics, ESCs have been used as models for
developmental biology and may also be useful for regenera-
tive medicine.
The characteristics or molecular mechanisms by which
mESCs maintain self-renewal or pluripotency have been
determined: mESCs have high alkaline phosphatase (AP)
activity, form tightly aggregated, three-dimensional colo-
nies, and maintain their pluripotent character by stable
expression of core pluripotent transcription factors such asccess article under the CC BY-NC-SA license
76 M. Ozawa et al.NANOG, OCT4, or SOX2, in response to stimulation of the
Janus kinase/Just another kinase (JAK) and signal transducer
and activator of transcription3 (STAT3) pathway by leukemia
inhibitory factor (LIF) in serum containing medium (Smith
et al., 1992; Niwa et al., 2009). More recently, it has been
shown that combined treatment with two small molecule
inhibitors (named 2i), the mitogen-activated protein kinase/
extracellular regulated kinase (MAPK/ERK) kinase inhibitor
PD0325901 and the glycogen synthase kinase 3 beta (GSK3ß)
inhibitor CHIR99021 (Ying et al., 2008; Marks et al., 2012),
maintains the cells in an early naive state, called the
‘ground state’, which is characteristic of ESCs.
In addition to mESCs, ICM-originated pluripotent stem cells
have been established from human (Thomson et al., 1998) or
non-human primate (Thomson et al., 1995; Sasaki et al., 2005)
cells. Hence, human or primate ESCs havemany characteristics
similar to mESCs, such as a stable capacity for self-renewal in
vitro and the potential to generate derivatives of all three
germ layers (Thomson et al., 1998). However, the morphology
and cytokine/growth factor dependency that supports self-
renewal in human ESCs are quite different from that in mESCs.
Human ESCs form flat, two-dimensional colonies, have low
trypsin tolerance during passage (Watanabe et al., 2007;
Ohgushi et al., 2010), and express the core pluripotency-
maintaining transcription factors such as NANOG, OCT4, and
SOX2, by activating ERK1/2- and SMAD2/3-mediated signal
transduction in response to FGF2 and ActivinA, respectively.
Another pluripotent cell line in mice developed from early
epiblast cells of a postimplantation E5.5 to E6.5 fetus, which is
called epiblast stem cell (EpiSC), is thought to resemble human
ESCs more than mESCs (Brons et al., 2007; Tesar et al., 2007;
Hayashi and Surani, 2009). Like human ESCs, EpiSCs form large,
flat, two-dimensional colonies, and grow upon stimulation by
FGF2 and ActivinA (Brons et al., 2007; Tesar et al., 2007;
Greber et al., 2010).
Activation of ERK1/2 by FGF2 is a key signal transduction
pathway that maintains the self-renewal state of human
ESCs or EpiSCs, whereas stimulates differentiation of mESCs
(Hamazaki et al., 2006; Kunath et al., 2007; Nichols and
Smith, 2009). Likewise, the pluripotent character of human
ESCs or EpiSCs cannot be maintained in 2i/LIF culture
conditions (Guo et al., 2009; Hanna et al., 2010). Based on
these different cytokine dependencies, numerous studies
have attempted to revert primed human ESCs or mouse
EpiSCs to a naive or ground state by changing their growth
factor, or cytokine dependency, from FGF2/ActivinA to LIF
and/or 2i (Zhou et al., 2010; Hanna et al., 2010).
Murine induced pluripotent stem cells (iPSC) (Takahashi and
Yamanaka., 2006), which can be routinely established and
maintained in the presence of LIF, can also be developed by
exposure to FGF2, and possess full pluripotency as determined
by chimera production (di Stefano et al., 2010). In addition,
another type of self-renewing stem cells from preimplantation
murine embryos can be established in response to FGF2,
ActivinA, and the Gsk3ß inhibitor BIO (designated FAB-SC).
FAB-SC has no naive pluripotency while they cannot form
teratomas or contribute chimera after blastocyst injection,
whereas they recovered naive pluripotencywhen they cultured
in LIF-containing medium (Chou et al., 2008). These previous
reports suggest that pluripotent stem cells exhibit plasticity in
their cytokine dependence, especially during the time of their
derivation.To examine the plasticity in growth factor/cytokine
dependency in pluripotent stem cells, we established a unique
embryonic stem cell line from the ICM of mouse preimplanta-
tion blastocysts using the culture environment previously
reported for supporting development and maintenance of
EpiSCs, i.e., an FGF2 and serum replacement containing
culture medium onmitotically inactivated feeder cells (mouse
embryonic fibroblasts, MEFs). Unexpectedly, our ICM-derived
stem cells (termed FGF-ESCs) could self-renew in this culture
condition and had similar characteristics to naive mESCs, e.g.,
high AP activity, tightly packed 3-D colonies, and tolerance
to trypsin during passage. FGF-ESCs can form teratomas in
immunodeficient mice. In addition, a striking feature of the
FGF-ESCs is that they are competent to contribute to chimeric
mice, including their germ cells, with high efficiency, despite
being maintained in the same culture conditions as ‘chimera-
unqualified’ EpiSCs. Therefore, the data presented in this
study could provide novel insights into the roles of cytokines
and growth factors in maintaining pluripotency and the
mechanisms that distinguish between the naive and primed
states.
Materials and methods
Derivation and maintenance of FGF-ESCs, EpiSCs,
and ESCs
C57BL/6J, MCH or NOD–SCID (NOD/ShiJic-scid) strain mice
were purchased from Clea-Japan (Tokyo, Japan), and NOD/
ShiLtJ strain mice were purchased from Charles River
(Yokohama, Kanagawa, Japan). Embryos were produced by
natural matings with the same strain males and females.
Embryos were collected on day E1.5 by flushing the oviduct
or E3.5 by flushing the uterus of the pregnant female,
respectively. E1.5-collection embryos were pre-cultured for
2 days in modified Whitten's medium (mWM) to produce
blastocysts, whereas E3.5-collection blastocysts were served
for following experiment without pre-culture. Each blasto-
cyst was transferred to a well in a 24-well culture plate
(BD Biosciences, Bedford, MA, USA) containing irradiated
MEFs (1.2 × 105/cm2) in K15F5 medium (Najm et al., 2011)
without any additional growth factors or cytokines. All
medium components except fetal bovine serum (FBS) were
purchased from Life Technologies (Life Technologies, Tokyo,
Japan); FBS was obtained from HyClone (Thermo Scientific,
Tokyo, Japan). Six to eight days after initiation of outgrowth
formation, embryonic cell-derived colonies were partially
dissociated by exposure to 0.25% trypsin-EDTA for 3 min
followed by gentle pipetting to produce small clumps of
cells. Cell clumps were passaged to fresh K15F5 medium
with MEFs and without growth factor or cytokine additives
and cultured for an additional 5 to 7 days. At this point, two
distinct types of colonies were observed in the same well:
large, flat colonies morphologically like EpiSCs and small,
dome-shaped colonies morphologically like ESCs. ESC-like
colonies, termed FGF-ESCs, were collected and disaggre-
gated into single cells in 0.25% trypsin-EDTA and passaged
onto fresh MEFs precultured in EpiSC culture medium
(EpiSCM, Knockout-DMEM with 20% Knockout serum replace-
ment (KSR), 2 mM GlutaMax, 1X non-essential amino acids,
0.1 mM beta-mercaptoethanol (all from Life Technologies),
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FGF-ESCs were passaged every 2 to 3 days at a subculture
dilution of 1:10. EpiSC-like colonies were also collected and
dissociated by vigorous pipetting into small clumps and
passaged to EpiSCM containing fresh MEFs and served as an
EpiSC control for each experiment (Najm et al., 2011). The
medium used for culture of FGF-ESCs was EpiSCM, to which
specific cytokines or inhibitors were added as indicated
throughout the manuscript. Another set of blastocysts
developed in vitro from E1.5 embryos was used for ESC
development. In brief, blastocysts were transferred to ESC
medium (ESCM, DMEMwith 15% FBS, 2 mM L-glutamine, 0.1 mM
beta-mercaptoethanol) containing 2i (1 μM PD0325901
(Stemgent, San Diego, CA, USA), and 3 μM CHIR99021
(Axon Medchem, Groningen, Netherlands), Nichols et al.,
2009), and 1000 U/ml LIF in the presence of MEFs for initiating
ICM outgrowth. Five to seven days after the transfer, ICM
outgrowth colonies were disaggregated into single cells by
0.25% trypsin-EDTA and passaged onto fresh MEFs precultured
in ESCM. After the third passage, ESCs were cultured in ESCM
with 2i/LIF without MEFs, and passaged every other day at a
1:10 dilution. All mouse work was performed in compliance
with the guidelines of the Institutional Animal Care and Use
Committee of the University of Tokyo.
AP staining
AP activity was determined by using the Alkaline Phospha-
tase Assay Kit (Sigma-Aldrich, St. Louis, MO, USA) according
to the manufacturer's instructions. AP staining was per-
formed 3 days after passage.
ROCK inhibitor treatment
FGF-ESCs were disaggregated in to single cells by 0.25%
trypsin-EDTA and passed (1 × 104 cells/well in 12-well plate)
on fresh MEF in EpiSCM containing FGF2 with or without
ROCK inhibitor (Y27632, 10 μM, Stemgent). Two days post
passage, colonies were stained with the AP assay kit and
numbers of AP positive cells were counted.
Chromosome counting
FGF-ESCs at 48 hour post-passagewere treatedwith 100 μg/ml
colcemid (KaryoMAX Colcemid Solution in PBS, Life Technolo-
gies) for 2 h. Then, colonies were detached from MEF by
exposure of collagenase type IV solution (1.5 mg/ml in EpiSCM)
and collected to a new tube. Collected colonies were
disaggregated into single cells by 0.25% trypsin-EDTA, and
cells were resuspended in hypotonic solution (0.56% (w/v)
KCl in water) and incubated for 20 min at 37 °C. After the
incubation, cells were centrifuged, hypotonic supernatant
was removed, and methanol/acetic acid solution (3:1) was
added dropwise to the cell pellet for fixation. This fixation
procedure, add fixative followed by centrifugation and
removal of supernatant, was repeated four times. Then,
fixed cells were spread onto a glass slide and dried at 37 °C
for 3 to 7 days. Chromosomes on the slides were stained with
Giemsa (KaryoMAX Giemsa Stain Solution, Life Technologies)
using the method described by The Jackson Laboratory(http://www.jax.org/cyto/gcbands.html), and the number
of chromosomes were counted.
Teratoma formation
FGF-ESCs were disaggregated using 0.25% trypsin-EDTA, and
1 × 106 cells were injected intraperitoneally into NOD–SCID
mice. Three to five weeks after transplantation, tumor(s) were
collected, fixed with 4% paraformaldehyde, and processed for
paraffin sectioning. Sections were observed following Hema-
toxylin and Eosin staining.
GFP transfection and chimera analysis
To establish GFP reporter FGF-ESCs, cells were co-transfected
with Super PiggyBac Transposase vector and PB513B vector
(System Bioscience, Mountain View, CA, USA) using Xfect Stem
Transfection Reagent (Clontech, Mountain View, CA, USA). To
select stable transfectants, cells were cultured on DR4 MEF
(Applied Stem Cell, CA, USA) in the presence of puromycin
(2 μg/ml) for a week. Ten to fifteen dissociated GFP
transfected FGF-ESCs were injected into MCH blastocysts. A
group of injected blastocysts (10 blastocysts) was used to
observe integration of injected cells into the ICM on the
following day in vitro. Another set of injected blastocysts was
transferred on the same day of injection to uteri of MCH
surrogate mothers mated with vasectomized males 2 days
earlier. Chimeras were determined by coat color mosaicism
and germ line contribution was tested by mating with wild-
type C57/BL6J mice.
RNA quantification by real time PCR
All samples used for quantitative real time PCR (qPCR) were
harvested 2 days after passage. Total RNA from cultured
cells was extracted using Sepasol-RNA I Super G (Nacalai
Tesque, Kyoto, Japan), and treated with DNaseI (Takara,
Shiga, Japan) to digest potentially contaminating genomic
DNA. Total RNA (500–800 ng) was used to synthesize cDNA
using SuperScript VILO (Life Technologies) according to the
manufacturer's instructions in a reaction volume of 10 μl,
which was subsequently diluted 2-fold with water. The cDNA
(1.5 μl) was used for qPCR analysis (Applied Biosystems
StepOne, Life Technologies) in a PCR reaction mixture of
10 μl containing 1X Fast SYBR Green mix (Life Technolo-
gies), and 0.3 μM each of forward and reverse primers. The
primer sets used in this study are listed in Supplemental
Table S2. The fold difference was calculated using the ΔΔCt
method (Schmittgen and Livak, 2008) with Gapdh as a
reference.
Bisulfite sequencing of genomic DNA
Genomic DNA from ESCs, EpiSCs, or FGF-ESCs was extracted
using the Wizard Genomic DNA Purification kit (Promega,
Tokyo, Japan), and modified with bisulfite using the
MethylCode Bisulfite Conversion Kit (Life Technologies). CpG
regions in Rex1 or Stella were amplified by nested PCR using
specific primer sets (Supplemental Table S2) with ExTaq
polymerase (Takara) under the following conditions. The first
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30 s, 50 °C for 30 s, 72 °C for 1 min, and, finally, 72 °C for
5 min. Nested PCR was carried out under the conditions of
94 °C for 3 min, 30 cycles of 94 °C for 30 s, 46 °C for Rex1
or 44 °C for Stella for 30 s, 72 °C for 1 min, and, finally, 72 °C
for 5 min. PCR products were purified by agarose gel
electrophoresis, subcloned into T-Vector pMD20 (Takara),
and sequenced. Analysis of sequences and figure generation
was carried out using QUMA (http://quma.cdb.riken.jp/
top/quma_main_j.html).Immunocytochemical staining
Cells cultured on Lab-Tek Chamber Slides (Nunc, Thermo
Scientific) were fixed for 15 min in 2% paraformaldehyde,
washed in PBS, permeabilized and blockedwith PBS containing
1% BSA and 0.3% Triton X-100 for 1 h at room temperature
(RT). Then, cells were incubated with rabbit anti-STELLA
(Abcam, Cambridge, UK, 1:100), goat anti-BRACHYURY (R&D
Systems, Minneapolis, MN, USA, 1:30), or rabbit anti-SOX17
(Merck Millipore, Darmstadt, Germany 1:100) at 4 °C over-
night. Following the primary antibody exposure, cells were
washed in PBS containing 0.1% Tween 20 and incubated with
Alexa Fluor dye-conjugating secondary antibodies (Life Tech-
nologies, 1:1,000) for 1 h at RT in the dark. Nuclei were then
stained using DAPI (Sigma).Isolation of ICM from blastocyst by immunosurgery
The zona pellucida was removed from blastocyst by exposure
of Acidic Tyrode's solution (Merck Millipore). Zona-free
blastocyst was incubated with DMEM (Life Technologies)
containing anti-mouse serum (8 mg/ml, Sigma-Aldrich) for
45 min at 37 °C followed by 30 min incubation in DMEM
containing guinea pig complement (16.5 mg/ml, Rockland
Immunochemicals, PA, USA). Trophectoderm cells were
removed by repeated pipetting, and isolated ICM was used
for microarray analysis as described in the following section
(50 ICMs per replicate).Microarray analysis
RNA from each cell line was extracted using NucleoSpin RNA II
(Macherey-Nagel, Düren, Germany). RNA from isolated ICMs
was extracted using NucleoSpin RNA XS (Macherey-Nagel).
cDNA was synthesized using the Ovation Pico WTA System V2
(NuGEN, Sun Carlos, CA, USA) followed by fragmentation
and fluoro-labeling using the Encore Biotin Module (NuGEN)
according to the manufacturer's instructions. Samples were
hybridized to the Affymetrix Mouse Gene 2.1 ST Array Strip
(Affymetrix Japan, Tokyo, Japan) and analyzed using the
GeneAtlas System (Affymetrix). Statistical analysis and princi-
pal component analysis (PCA) was carried out using GeneSpring
(Agilent Technologies, Tokyo, Japan). Gene ontology (GO) for
differentially expressed genes was annotated by the Database
for Annotation, Visualization and Integrated Discovery
(DAVID; DAVID Bioinformatics Resources 6.7), http://david.
abcc.ncifcrf.gov/.Pathway inhibitor treatments
FGF-ESCs were treated with an activin receptor-like kinase
inhibitor (ALKi, SB431542, 20 μM, Stemgent, CA, USA), an
FGF-receptor inhibitor (FGFRi, PD173074, 100 nM, Stemgent),
or a JAK inhibitor 1 (JAKi, 0.6 μM, Merck Millipore) in the
maintenance culture condition (EpiSCM with FGF2), and
harvested after 2 days (for qPCR) or 3 days (for AP staining)
of culture.
Immunoblotting
Protein was extracted from each cell line by sonication in RIPA
buffer containing 1X Protease Inhibitor cocktail (Nacalai), and
analyzed by standard Western blotting protocols with the
following antibodies: rabbit anti-phospho-SMAD2/3 (1:2000),
rabbit anti-SMAD2/3 (1:1000), rabbit anti-phospho-STAT3
(1:2000), rabbit anti-STAT3 (1:2000), rabbit anti-phospho-
ERK1/2 (1:2000), rabbit anti-ERK1/2 (1:1000) (all primary
antibodies used for immunoblotting were purchased from
Cell Signaling Technology, Danvers, MA, USA), and second-
ary HRP-conjugated donkey anti-rabbit IgG (Santa Cruz,
Dallas, TX, USA, 1:10,000).
Feeder free culture of FGF-ESC
FGF-ESC colonies cultured onMEFwere detached by incubating
with collagenase type IV solution (1.5 mg/ml in EpiSCM), and
disaggregated into single cells by 0.25% trypsin-EDTA. Single
cells were seeded onto new well coated with FBS and cultured
in EpiSCM in the presence of FGF2 (10 ng/ml), LIF (1000 U/ml)
and ActivinA (20 ng/ml, R&D Systems, Minneapolis, MN, USA).
Statistical analysis
All numerical data are shown as the mean ± SEM for three
independent replications. Differences were tested by one-
way ANOVA followed by Tukey's multiple comparison tests.
Difference between means was considered significant at
P b 0.05.
Results
Establishment of embryonic stem cell lines from
E3.5 preimplantation embryos in response to
FGF2 stimulation
The ICM of the preimplantation blastocyst is heterogeneous,
and forms morphologically distinct 2-D or 3-D outgrowths at
early passages on MEFs without additional growth factors
or cytokine stimulation (Najm et al., 2011). To determine
the potential plasticity in growth factor dependency in
ICM-originated early outgrowth cells, we used preimplanta-
tion E3.5 blastocysts (C57BL/6J), which were collected on
E1.5 from the oviduct and pre-cultured for 2 days in mWM or
collected on E3.5 from uterus, in cultures with feeder MEFs
without any additional cytokines or growth factors in K15F5
medium (Najm et al., 2011). In the primary culture, some
outgrowth colonies exhibited a tight, 3-D like morphology,
other outgrowths formed flat, 2-D colonies, and some contained












C57BL/6 J E1.5 19 3 15.8
C57BL/6 J E3.5 16 2 12.5
NOD E1.5 62 0 0
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2-D and 3-D, respectively). At the second passage without
growth factors or cytokine additives, two morphologically
distinct colonies emerged from the same blastocyst (Fig. 1 A,
top right, arrow and arrowhead indicating 2-D and 3-D,
respectively), and a stable EpiSC-like cell line was developed
from the 2-D outgrowth in response to FGF2 stimulation (Fig. 1
A, bottom left), in agreement with a previous study (Najm et
al., 2011). Surprisingly, ES-like 3-D outgrowths, which formed
small, tight, shiny colonies, also could be propagated in the
same culture conditions used for EpiSC cultures (KSR and FGF2
on MEFs) for longer periods (at least 35 passages over 3 months)
without changing their ES-like 3-D shape (Fig. 1 A, bottom
right). Yielding efficiencieswere shown in Table 1.We also tried
to develop self-renewing cell lines from NOD strain embryos by
using the same procedure, but no stable colonies could be
obtained after the third passage when outgrowth was disaggre-
gated into single cells by trypsin (0 line from 62 embryos)
(Table 1).
Next, we tested AP activity in FGF-ESCs. AP activity is a
classic hallmark of pluripotent stem cells and is high in ESCs,
but less evident or absent in EpiSCs (Brons et al., 2007; Zhou
et al., 2010). Although EpiSCs did not have AP activity,
FGF-ESCs showed high AP activity (Fig. 1 B). Another distinction
between ESCs and EpiSCs is that ESCs tolerate single cellFigure 1 Development of FGF-ESCs. (A) Top left: primary ou
dimensional (arrowhead) areas from a single blastocyst. Top right: se
flat colony (arrow) and a three-dimensional tight colony (arrowhe
colony (left) and three-dimensional ESC-like colony (termed FGF-ESC
10 ng/ml FGF2 on MEF). (B) AP staining of an EpiSC colony (top) or FG
or without (right) a Rho kinase (ROCK) inhibitor. (D) AP staining of F
(top right), or ESCs treated with FGF2 for 72 h (bottom). (E) Giemsa
ratio of cells having indicated number of chromosomes (right, n = 2disaggregation but EpiSCs do not. ESCs are routinely
passaged using trypsin and are disaggregated into single
cells. By contrast, EpiSCs or human ESCs lack tolerance to
trypsinization and are easily induced to undergo apoptosis
when disaggregated into single cells (Watanabe et al.,
2007). Therefore, these cells are routinely passaged by
milder methods, i.e., digesting colonies into small clumps
by collagenase or vigorous pipetting. To test the tolerance
of FGF-ESCs for single cell disaggregation, a cell attachment
test was conducted. FGF-ESC colonies were digested by
trypsin into single cells and seeded onto freshly prepared
MEFs in the presence or absence of the Rho kinase (ROCK)
inhibitor Y27632 which is known to increase survivability intgrowth containing two-dimensional flat (arrow) and three-
condary colonies from one blastocyst showing a two-dimensional
ad). Bottom: stably self-renewing two-dimensional EpiSC-like
, right), developed in the same culture conditions (20% KSR with
F-ESCs (bottom). (C) AP staining of FGF-ESCs cultured with (left)
GF-ESCs treated with FGF2 (top left), ESCs treated with 2i/LIF
staining of chromosomes in FGF-ESC at M-phase (left), and the
6).
Table 2 Delivery ratio and chimeric contribution after
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80 M. Ozawa et al.human ESCs (Watanabe et al., 2007; Ohgushi et al., 2010)
and EpiSCs (Greber et al., 2010) after disaggregation into
single cells. Addition of 10 μM Y27632 did not promote cell
survival after single cell disaggregation (1 × 104 cells/well
were seeded into a 12-well plate, and 1374 ± 94 and 1921 ± 134
AP-positive colonies were observed per well in the presence or
absence of Y27632, respectively, Fig. 1 C). Next, to investigate
whether ESCs could maintain their characteristics when
stimulated with FGF2 and grown on MEFs, ESCs were cultured
in the same conditions as FGF-ESCs and their AP activity was
determined. AP activity rapidly disappeared in ESCs during the
72 h after withdrawal of 2i/LIF and administration of FGF2
(Fig. 1 D). We then counted the number of chromosomes for
checking the stability of chromosome segregation in FGF-ESCs.
Although only one M-phase cell had 41 chromosomes, 25 cells
out of 26 M-phase cells had normal 40 chromosomes (96.2%,
Fig. 1 E). These results indicate that FGF-ESCs self-renew
stably but have distinct characteristics for their self-renewal
compared to ESCs or EpiSCs.Pluripotent characters including germ line
competency in the FGF-ESCs
To investigate the differentiation capacity of the FGF-ESCs
in vivo, a teratoma assay was conducted by intraperitoneal
injection of cells into immunodeficient mice (NOD-–SCID
mice). Transplanted cells formed teratomas consisting of all
three germ layers (Fig. 2 A), indicating that FGF-ESCs possess a
high degree of pluripotency. To determine their pluripotency
further, we tried to produce chimeric mice by injecting the
GFP reporter-integrated FGF-ESCs (GFP-FGF-ESCs) into pre-
implantation blastocysts (MCH strain) and cultured one day in
vitro, or transferred the embryos into surrogate mothers. A
day after the blastocyst injection, all the blastocysts (n = 10)
showed integration of GFP-FGF-ESCs into the ICM as indicated
by GFP fluorescence (Fig. 2 B). Contribution of GFP-positive
cells in the fetus was also observed at E17.5 (Fig. 2 C). A
total of 80 blastocysts were injected with GFP-FGF-ESCs
and transferred into surrogate mothers, and 50 pups were
delivered. Of the offspring, 66% (33 out of 50) were chimeric
as confirmed by their coat color (Table 2). In addition to the
somatic contribution, pure black hair second generation mice
were born when a chimeric male was mated with a C57BL/6J
female (Fig. 2 D, arrow). These results confirmed that
FGF-ESCs have full pluripotency comparable with mouse ESCs.Gene expression pattern and epigenetic status of
FGF-ESCs
To investigate transcriptome similarities among FGF-ESCs,
ESCs, and EpiSCs, a microarray analysis was conducted usingthe Affymetrix GeneAtlas system with the Mouse Gene 2.1 ST
Array. In addition to the three pluripotent cell lines, ICMs
were isolated from E3.5 blastocysts by immunosurgical
removal of trophectoderm cells and served as an in vivo
control. PCA showed that all four cell types are distinct
whereas ESC and EpiSC are relatively close to each other
compared to E3.5 ICM or FGF-ESCs (Fig. 3 A). The Gene
Expression Omnibus (GEO) database accession number for
the microarray raw data analyzed in this study is GSE53275.
The accumulated GO terms are provided in Supplemental
Tables S1.
We further quantified the expression levels of genes that
have important roles in pluripotency, or genes that are
naive/primed status-specific markers in ESCs or EpiSCs by
qPCR. Expression levels of core pluripotent factors such as
Nanog or Oct4 were comparable between FGF-ESCs, ESCs,
and EpiSCs. On the other hand, FGF-ESCs expressed EpiSC
markers such as Gata6, Fgf5, Brachyury (also known as T), or
Cer1, all of which were almost absent in the ESCs, whereas
Sox17 expression was quite low, similar to ESCs. On the
other hand, FGF-ESCs also expressed naive markers as Klf4,
Stella, and Pecam1 at levels comparable to ESCs, whereas
expression of these geneswas almost absent in EpiSCs (Fig. 3 B).
An anti-STELLA or anti-BRACHYURY antibodies showed that
almost FGF-ESCs were both STELLA and BRACHYURY positive,
whereas only STELLA was present in ESCs, and only BRACHYURY
was present in EpiSCs (Fig. 3 C).
Next, we determined similarities among epigenetic mod-
ifications at the specific regions in the three cell types. The
promoter regions of Rex1 and Stella are demethylated in ESCs,
but are methylated in EpiSCs (Bao et al., 2009). In agreement
with those previous studies, we also observed that the
promoters were highly methylated in the EpiSCs, but not in
the ESCs (Fig. 3 D, 60.0% vs. 7.5% at the Rex1 promoter and
87.9% vs. 5.3% at the Stella promoter, respectively). Interest-
ingly, the Rex1 and Stella promoters were demethylated in
the FGF-ESCs similar to the ESCs (Fig. 3 D, 5.1% at Rex1 and
15.8% at Stella).Conversion of FGF-ESCs to ESC-like status in 2i and
LIF treated cultures
We examined whether the FGF-ESCs could grow in the
absence of feeder MEFs. FGF-dependent EpiSCs were grown
in feeder-free cultures on fibronectin coated dishes in the
presence of ActivinA and FGF2 (Greber et al., 2010; Gillich
et al., 2012). In contrast to EpiSCs, FGF-ESCs differentiated
quickly in the absence of MEFs. The FGF-ESC colonies could
never be maintained in feeder-free conditions even when
cultured with FGF2 alone or FGF2 and ActivinA (Fig. 4 A),
suggesting that they need additional stimuli to maintain
their self-renewal capacity.
Next, we tested the potential of FGF-ESCs to convert to
an ESC-like naive state. Conversion of primed EpiSCs back to
naive ESCs occurs rarely, even when EpiSCs are stimulated
with LIF or 2i/LIF, treatments that maintain the ground state
of ESCs (Zhou et al., 2010; Guo et al., 2009). To examine
the sensitivity of FGF-ESCs to LIF and/or 2i stimulation, we
cultured FGF-ESCs in EpiSCM with 2i, LIF, or 2i/LIF, in the
absence of FGF2 and MEFs. Interestingly, 2i alone could not
maintain colony formation (Fig. 4 B, top right) suggesting
Figure 2 Potential of pluripotency in FGF-ESCs. (A) Teratoma generated from FGF-ESCs (top left). HE-stained sections showing
ectoderm (top right), endoderm (bottom left), and mesoderm (bottom right). (B) E4.5 hatching blastocyst 1 day after the
GFP-FGF-ESC injection. (C) E17.5 GFP-FGF-ESC chimeric fetus. (D) Chimeric male produced by FGF-ECS injection into blastocyst (MCH
strain) followed by the embryonic transfer to a surrogate mother. Germ-line contribution of FGF-ESCs was verified by black coat-color
of pups (arrow) produced by mating with wild-type B6 female.
81Development of FGF2ependent pluripotent stem cells showing naive state characteristicsthat inactivation of ERK1/2 and GSK3β is not sufficient to
promote FGF-ESC self-renewal or transformation to ESC-like
state. Some FGF-ESCs, however, formed small, tight 3-D
colonies when cultured with LIF at the first passage (Fig. 4 B
top left) although they all died or differentiated after the
second passage in the LIF only condition. By contrast, a
certain number of colonies could be propagated in cultures
exposed to both 2i and LIF, and they could be propagated in
the 2i/LIF culture condition with maintaining their colony-
forming abilities (N10 additional passages) (Fig. 4 B, bottom).
Fluctuation of marker gene expression in FGF-ESCs under
2i/LIF conditions was examined by qPCR. Expression of the
naive state marker Nanog in FGF-ESCs in the 2i/LIF culture
condition was stable and comparable to that in ESCs.
Pecam1 expression was also stable and significantly lower
at the first and second passages under the 2i/LIF culture
condition than ESCs. However, Stella expression, which was
higher in FGF-ESCs stimulated with FGF2 than ESCs, became
lower at the second passage in the 2i/LIF culture condition
than in ESCs. On the other hand, expression of the primed
state markers Gata6 and Brachyury was decreased in 2i/
LIF-treated FGF-ESCs, and was not significantly different to
that in ESCs after two passages (Fig. 4 C). These results suggest
that FGF-ESCs have partial potential to change to a naive
state-like by stimulation with 2i/LIF.Combined stimulation with FGF2, LIF and ActivinA
sustain FGF-ESC self-renewing proliferation without
support from MEFs
Our data suggest that FGF2 alone is not sufficient for
maintaining self-renewal of FGF-ESCs in the absent of MEF,
and that they are sensitive to LIF, to some extent. In ESCs, the
LIF mediated JAK/STAT3 pathway is essential for maintaining
the pluripotent character of the cells, whereas FGF2 stimula-
tion induces differentiation (Smith et al., 1992; Nichols and
Smith., 2009). By contrast, EpiSCs grow under FGF2 stimula-
tion and LIF has little effect onmaintaining EpiSCs (Nichols and
Smith., 2009). Therefore, we investigated which pathways are
essential for maintaining FGF-ESCs. In contrast to the ESCs or
EpiSCs, the SMAD2/3, STAT3, and ERK1/2 pathways were
activated in FGF-ESCs (Fig. 5 A), indicating that these three
signal transduction pathways have roles in maintaining
FGF-ESCs. The importance of these pathways in maintaining
FGF-ESCs was examined by using specific inhibitors. Treat-
ment of FGF-ESCs with ALKi (SB431542, 20 μM) or FGFRi
(PD173074, 100 nM) did not affect the AP activity of FGF-ESC
colonies, whereas a JAK inhibitor 1 (JAKi, 0.6 μM) caused an
increase in AP-low colonies (Fig. 5 B, arrows), and the
JAKi-treated colonies assumed a large, flat shape as early as
the second passage after inhibitor treatment (Fig. 5 C).
Figure 3 Gene expression pattern and epigenetic status of FGF-ESCs. (A) Principal component analysis (PCA) of RNAs from FGF-ESCs, EpiSCs, ESCs, and E3.5 ICMs. (B) qPCR analysis
of marker gene expression in FGF-ESCs, ESCs, and EpiSCs. Expression of each gene was standardized using Gapdh, and expression levels of each gene in ESCs were designated as 1-fold
(n = 3 in each cell type). (C) Immunocytochemical analysis of STELLA and BRACHYURY in FGF-ESCs (top), ESCs (middle), and EpiSCs (bottom). DAPI staining is shown on the right. (D)









Figure 4 FGF-ESCs cannot be maintained in FGF2 and ActivinA without MEFs, whereas can be promoted to an ESC-like state in 2i/LIF.
(A) MEF-free culture of control EpiSCs with FGF2 and ActivinA (top), FGF-ESCs with FGF2 (bottom left), or FGF2 and ActivinA (bottom
right). (B) MEF-free culture of FGF-ESCs in LIF (top left), 2i (top right), or 2i and LIF (bottom). (C) Fluctuation of gene expression in
FGF-ESCs cultured in 2i and LIF without FGF2 and MEFs at the first passage (ps1) or the second passage (ps2). FGF-ESCs cultured in EpiSCM
with FGF2 and MEF were served as control. The expression level of each gene in ESCs is designated as one and shown as a blue dot.
Different superscripts depict significant differences within each panel (n = 3 replicate studies, P b 0.05). NS means no significance.
83Development of FGF2ependent pluripotent stem cells showing naive state characteristicsExpression of genes correlated with the primed state, such as
Fgf5 or Brachyury, was drastically reduced when FGF-ESCs
were cultured with FGFRi or ALKi, whereas Fgf5 was increased
by JAKi treatment (Fig. 5 D). Concomitantly, expression of
Klf4, known naive state marker, was significantly lowered by
JAKi treatment; by contrast, expression of Klf4 did not change,
and Stella and Nanog increased in response to FGFRi treatment
(Fig. 5 D). These results indicate that the FGF-FGFR, SMAD, and
JAK/STAT3 pathways are important for maintaining FGF-ESCs,
but the roles of each are distinct. Inhibition of the FGFR
or SMAD pathways facilitates transition of FGF-ESCs to the
ESC-like naive state, whereas inhibition of the JAK/STAT3
pathway promotes progression to the EpiSC-like primed state.
Feeder free culture of FGF-ESC in the presence of
FGF2, ActivinA and LIF
Our data led us to hypothesize that LIF-JAK/STAT3-,
FGF-FGFR-, and ActivinA-SMAD-mediated signal transductionpathways have critical roles in maintaining FGF-ESC charac-
teristics. To evaluate this hypothesis further, we cultured
FGF-ESCs in feeder-free conditions with FGF2, ActivinA, and
LIF in EpiSCM (all the following experiments were carried out
using cells after 10 passages or more in this feeder-free
culture condition). Surprisingly, FGF-ESCs could grow in
these feeder-free culture conditions with having their high
AP activity (Fig. 6 A), and 26 out of 28 M-phase cells have
normal 40 chromosomes, although one cell each had greater
(41) or lesser (39) number of chromosomes, respectively
(Fig. 6 B). Next, gene expression patterns in the feeder-free
FGF-ESC were compared with that with MEF by qPCR.
Expression levels of genes related to pluripotency such as
Oct4 or Nanog in feeder-free FGF-ESCs were comparable
with FGF-ESCs with MEF. On the other hand, primed state
markers such as Gata6, Fgf5 or Brachyury became lower at
2-fold or less in feeder-free FGF-ESCs compared to FGF-ESCs
with MEF, whereas another primed state marker Cer1 did not
differ much in either groups. Interestingly, Sox17 showed a
Figure 5 Activated signal transductions under FGF2, ActivinA or LIF mediated pathway in FGF-ESCs. (A) Immunoblot showing
phosphorylation pattern of SMAD2/3, STAT3, and ERK1/2 in ESCs, EpiSCs, or FGF-ESCs. Total protein was extracted from cells grown
in their basic culture conditions (2i/LIF in ESM without MEF for ESCs, or FGF2 in EpiSCM with MEFs for FGF-ESCs and EpiSC). (B) AP
staining of FGF-ESCs treated with an ALK inhibitor (top right), FGFR inhibitor (bottom left), or JAK inhibitor (bottom right). Arrows
indicate colonies losing AP activity. FGF-ESCs without inhibitor treatment are shown as controls (top left). (C) Morphology of FGF-ESCs
treated with each inhibitor at second passage (6 day post-treatment initiation). (D) qPCR analysis of gene expression in FGF-ESCs
treated with inhibitors against FGFR (purple), ALK (green), JAK (red), or without inhibitor (blue). Different superscripts depict
significant differences within each panel (n = 3 replicate studies, P b 0.05). NS means no significance.
84 M. Ozawa et al.great increase in feeder-free FGF-ESCs compared to FGF-
ESCs with MEF (Fig. 6 C). SOX17 protein (Suppelemental
Fig. 1A) as well as STELLA (Supplemental Fig. 1B) was also
present in almost feeder-free FGF-ESCs whereas only a few
numbers of FGF-ESC with MEF were SOX17 positive (Supple-
mental Fig. 1A, arrows). Since Sox17 expression in FGF-ESCs
with MEF is less evident like ESCs, and the expression level is
almost 20-fold weaker than EpiSC (Fig. 3 B), Sox17 levels
in feeder-free FGF-ESCs seem not too great but became
comparable with EpiSC. Interestingly, this culture condition,
e.g., FGF2, Activin A and LIF in EpiSCM could not support
self-renewal of ESCs (Supplemental Fig. 2), further supporting
that FGF-ESCs have distinct cytokine dependency compared
with ESCs. Lastly, potential for chimeric contribution of
FGF-ESCs in the feeder-free condition was determined by
cellular injection into blastocyst followed by the embryo
transfer to surrogate mother. Feeder-free FGF-ESCs contrib-
uted to ICMs after blastocyst injection (Fig. 6 D, upper panel),
and formed chimeras (46.4%, 13 out of 28 pups, Fig. 6 D, lower
panel). These data demonstrate that activation of FGF-FGFR,
ActivinA-SMAD, and LIF-JAK/STAT3 signals is indispensable for
maintaining the pluripotency of FGF-ESCs and their compe-
tence in contributing to embryonic tissues, as indicated by
chimera formation.Discussion
In the present study, we have developed a unique stem cell
line from preimplantation mouse blastocysts using culture
conditions that support development and maintenance of
mouse EpiSCs or human ESCs (Brons et al., 2007; Tesar et al.,
2007; Greber et al., 2010). Growth factor dependency is an
essential limiting factor in distinguishing characteristics of
pluripotency, such as a LIF-dependent naive state or an
FGF2/ActivinA-dependent primed state. However, some
recent studies show that naive state pluripotent stem cells
can be developed and proliferate without LIF or 2i. For
example, Chou et al. have developed a novel stem cell line,
named FAB-SC, from preimplantation ICMs using medium
containing FGF2, ActivinA, and the GSK3ß inhibitor BIO
(Chou et al., 2008). Although the original FAB-SCs had no
potential to form teratomas or contribute to chimeras, the
cells obtain full pluripotency, including germline contribu-
tion in chimeras, after a short exposure to LIF and BMP4
followed by returning the cells to the original culture
conditions (FGF2/ActivinA/BIO) (Chou et al., 2008). Murine
iPSCs were developed and maintained in LIF containing
medium (Takahashi and Yamanaka., 2006), but murine iPSCs
can also be established in FGF2 culture conditions, and iPSCs
Figure 6 Feeder-free culture of FGF-ESC under the combined stimulation by FGF2, ActivinA, and LIF. (A) Representative
morphology of FGF-ESCs cultured without MEFs and treated with ActivinA, FGF2, and LIF (left), and AP staining of the MEF-free
FGF-ESCs (right). (B) Giemsa staining of chromosomes in FGF-ESC without MEF at M-phase (left), and the ratio of cells having
indicated number of chromosomes (right, n = 28). (C) qPCR analysis of marker gene expression in FGF-ESCs with or without MEF.
Expression of each gene was standardized using Gapdh, and expression levels of each gene in FGF-ESCs with MEF were designated as
1-fold (n = 3 in each cell type). (D) Integration of MEF-free cultured GFP-FGF-ESCs into ICMs of E4.5 blastocysts 1 day after the
injection of GFP-FGF-ESCs (top), and juvenile chimeric pups (bottom).
85Development of FGF2ependent pluripotent stem cells showing naive state characteristicsestablished using FGF2 also have an ESC-like pluripotency
confirmed by germline commitment in chimeras (termed
FGF-iPSc, di Stefano et al., 2010). These results are in
agreement with the present study in that our FGF-ESCs
exhibit an ESC-like full pluripotency since they not only form
teratomas, but also contribute to chimeras, including the
germ cells, suggesting that LIF and/or 2i dependency is an
important, but not exclusive, factor for ensuring pluripotent
naive or primed status. These previous reports and the present
results together suggest that embryo- or somatic cell-derived
pluripotent stem cells have a degree of plasticity that
responds to the culture conditions during their develop-
ment. Furthermore, recent breakthrough study showed that a
naive state human ESCs or iPSCs could be established in the
presence of LIF/FGF2/TGFß1 (a member of TGF-ß superfamily
same as ActivinA) although they need 4 more signal inhibitors
for stable propagation (ERK1/2, GSK3ß, JNK and p38) (Gafni et
al., 2013). FGF-ESCs, therefore, could provide a unique model
to determine the relationship between cellular potential
(naive pluripotency) and growth factor dependency.
ESCs lose AP activity, a classic marker for pluripotency, as
rapidly as within 72 h in culture conditions without 2i/LIF
(Wray et al., 2011; Betschinger et al., 2013). Our results also
showed that AP activity in ESCs disappeared within 72 h after
FGF2 stimulation, suggesting that differentiation of ESCs is
easily induced by withdrawal of self-renewing factors, such
as 2i/LIF, or by stimulation with FGF2. FGF-ESCs, however,
self-renew in the EpiSC culture conditions, i.e., FGF2 and KSRwith MEFs, and do not differentiate into an EpiSC-like
primed state or further. Combined administration of FGF2 and
ActivinA without MEFs, which is sufficient to maintain EpiSCs
(Greber et al., 2010), cannot induce FGF-ESC self-renewal. By
contrast, administration of LIF in addition to FGF2/ActivinA
substitutes for withdrawal of MEFs for FGF-ESC maintenance.
The LIF-sensitive character of FGF-ESCs is also confirmed by
immunoblotting detection of activated phospho-STAT3 in the
FGF-ESCs, or pathway-specific inhibitors of the JAK/STAT3
pathway which diminished the number of colonies with AP
activity and repressed expression of some important pluripo-
tent naive-state genes, such as Klf4, or Stella, and increased
expression of primed state-committed genes such as Fgf5.
Thus, LIF-mediated activation of the JAK/STAT3 pathway may
prevent FGF-ESCs from conversion to the EpiSC-like primed
state.
Although FGF-ESCs showed ESC-like characteristics, such
as LIF sensitivity, CpG methylation patterns at the Rex1 and
Stella promoters, and comparable expression levels of Klf4
or Stella to ESC, the 2i culture conditions, which allow ESCs
for self-renewing without feeder MEF (Ying et al., 2008;
Marks et al., 2012), do not support proliferation of FGF-ESCs
in feeder-free conditions. These results indicate that other
pathway(s) in FGF-ESCs are indispensable for their mainte-
nance. Our inhibitor experiment showed that FGF-ESCs form
AP-positive colonies on feeder cells in the presence of FGFR
or ALK inhibitors, which block signals downstream of the
FGF-FGFR or ActivinA-SMAD2/3 pathways, respectively. On
86 M. Ozawa et al.the other hand, in contrast to the changes in JAK inhibitor-
treated FGF-ESCs, inhibition of FGFR or ActivinA-mediated
signaling in FGF-ESCs resulted in gene expression patterns
more similar to ESCs, e.g., reduced expression of the EpiSC
markers Brachyury and Fgf5, and increased expression of
Nanog and Stella. Similar results were obtained from a study
using EpiSCs; inhibition of SMAD signaling using an ALK
inhibitor changes the morphology of EpiSC colonies from 2-D
to 3-D and enhances their AP activity, and this effect is more
pronounced when a FGFR inhibitor and a MAP kinase inhibitor
are co-administered with the ALK inhibitor (Zhou et al., 2010).
These results indicate that SMAD- and FGF-mediated signaling
pathways are essential for delineating FGF2-dependent FGF-
ESCs or EpiSCs to an ESC-like naive state. Taken together, this
study suggests that combined stimulation by LIF, FGF2, and
ActivinA is needed to sustain FGF-ESC proliferation, and that
LIF inhibits differentiation to the primed state, whereas FGF2
and ActivinA play an important role in blocking conversion to
an ESC-like naive state.
Interestingly, despite culture condition for FGF-ESCs and
previously reported chimera-competent FGF-iPSCs (di Stefano
et al., 2010) are quite similar, e.g., FGF2 and KSR with MEFs,
their cytokine dependency seems different. Pluripotency of
FGF-iPSCs, which is determined by the expression of exoge-
nous Oct4-GFP reporter, mainly depends on TGFß-SMAD
pathway but not LIF or its downstream JAK pathway (di
Stefano et al., 2010). JAK i treatment has little effect on
self-renewal of mouse EpiSC (Tesar et al., 2007) or human ESC
(Androutsellis-Theotokis et al., 2006), whereas gene knock-
down of Smad2 in EpiSC or human ESC induces commitment
of somatic lineages (Sakaki-Yumoto et al., 2013). Thus,
self-renewing mechanisms in FGF-iPSCs might resemble
to EpiSC but not mESC or FGF-ESCs. Recently, cell-line
dependent distinct developmental potential of EpiSCs has
been reported (Bernemann et al., 2011). For example, some
EpiSC lines have high potential for reversion to the
pluripotent naive state when they are cultured in 2i/LIF,
which is similar to FGF-ESCs, whereas others do not (Han et
al., 2010; Bernemann et al., 2011). Furthermore, a very
small population of EpiSC has potential for contribution of
chimeras (Han et al., 2010). Since FGF-ESCs show 2i/LIF
initiating transition to mESC-like state or have competency
to contribute chimeras, further analysis to compare
FGF-ESCs not only with mESC but also some specific EpiSC
lines would be demanded.
Several studies have attempted to generate naive state
pluripotent stem cells from animals other than mice by
modifying their cytokine dependency from FGF2/ActivinA to
LIF and/or 2i (Zhou et al., 2010; Hanna et al., 2010). The
novel cell model reported in the current study will provide
further insights into the cytokine-mediated mechanisms that
maintain naive state pluripotency.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2014.04.012.
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